Parabilis Medicines, Inc.

Clinical-stage company developing Helicons, stabilized alpha-helical peptides designed to modulate intracellular disease drivers. Lead beta-catenin inhibitor zolucatetide is in Phase 1/2 testing across desmoid tumors and other Wnt-driven diseases; earlier programs include targeted protein degraders.